Table 1.

Tumor response assessment by two metabolic criteria (EORTC criteria and PERCIST)

	EORTC	PERCIST
Complete metabolic response (CMR)	Complete resolution of FDG uptake in all lesions	Complete resolution of FDG uptake in all lesions
Partial metabolic response (PMR)	≥ 25% Reduction in the sum of SUVmax after more than one cycle of treatment	≥ 30% Reduction of the SULpeak and an absolute drop of 0.8 SULpeak units
Progressive metabolic disease (PMD)	≥ 25% Increase in the sum of SUVmax or appearance of new FDG-avid lesions	≥ 30% Increase in the SULpeak of the FDG uptake and an absolute increase of 0.8 SULpeak, or appearance of FDG-avid new lesions
Stable metabolic disease (SMD)	Not qualify for CMR, PMR, or PMD	Not qualify for CMR, PMR, or PMD

EORTC, European Organization Research and Treatment of Cancer; PERCIST, Positron Emission Tomography Response Criteria in Solid Tumors; FDG, fluorodeoxyglucose; SUVmax, maximum standardized uptake value; SULpeak, peak lean body mass SUV.